# 第11屆 台 · 醫藥交流會議

The 11 th Joint Conference of Taiwan and Japan on Medical Products Regulation



#### Dr. Shou-Mei Wu, Director-General Taiwan Food and Drug Administration (TFDA)



## Outline

- 1 Medicinal Products
  - **Medical Devices**





4

2

Collaboration with Japan





## Outline



Medical Devices



Collaboration with Japan


#### **Future Prospects**




# **Drug Safety Monitoring**

#### Regulations for Drug Safety Monitoring

#### 2023.01.01



## Developing Regulations for Regenerative Medicine



Regenerative Medicinal Product Act (draft) 再生醫療製劑條例

To regulate the clinical practice of regenerative medicine at medical institutes

To regulate the product life-cycle of regenerative medicinal products



Act for the Development of Biotech and Pharmaceutical Industries

(revised Dec. 03, 2021) 仕坛高学孫国修제

生技產業發展條例

To facilitate the development of advanced medical and hightech products in Taiwan, including regenerative medicines



## Pilot Program for Publishing the New Drug Review Reports

- To enhance regulatory transparency
  - For global regulatory authorities and industries to have better understanding on regulatory decision making and review considerations of TFDA/CDE

Publishing New Drug Review Report in Summarized format was originally implemented in 2010

Publishing New Drug Review Full English Report (with defined format) Start as a 2-year pilot program on July 1<sup>st</sup>, 2023

New Drugs (new active pharmaceutical ingredient, including biologics) with one of the following features :

Domestic product

bose


- Global-first approved
- ✓ Regenerative medicinal products
- ✓ Identified with ethnical sensitivity based on the results of BSE
- ✓ Approved indication different from EU/US/Japan

Currently not applicable for Orphan Drugs




## **Real-World Data and Evidence in Drug Application**

- Guidelines in Taiwan




## **Elements of Decentralized Clinical Trials**




Issued "Guideline on the implementation of decentralized elements in clinical trials with medicinal products" in June 2023.



## **Regulatory Updates in BA/BE**



## Promote electronic drug package inserts (e-labeling)



## Outline



Medical Devices



Collaboration with Japa


#### **Future Prospects**



2

3

# 2023 Regulatory Updates on Medical Devices



# Strategies for Promoting the SaMD Industry


#### **Consultation Service**

- ↓ Product time-to-market
- For domestic AI-SaMDs
- 12 AI-SaMDs launched (From 2021 to July 2023)

MDs e-Learning platform	
2021 WELCOME TO 醫療器材及化粧品數	立學習網
新版上	and the second se

#### **Training Courses**

- Meeting industry needs
- 140+ courses
- MDs e-learning platform



#### **Guidelines Developed**

- Regulatory environment
- 17 documents published
  - $\checkmark$  11 guidelines
    - (4 related to AI-SaMDs)
  - $\checkmark$  1 reference template

#### **AI/ML** Platform


- Information and matchmaking
- Views : 34,000+ (From 2021 to July 2023)





SaMD: Software as a Medical Device

## Status of Approved AI-SaMDs in Taiwan



MI: Myocardial infarction

AMD: Age-related macular degeneration

## **International Cooperation**



Asia-Pacific Economic Cooperation

 RHSC Medical Device Priority Work Area Center of Excellence (CoE) for Regulatory Science (since 2019)

- IMDRF International Medical Device Regulators Forum
- Affiliate Member (2023)



- Work Group 2 Pre-market: IVDD Chair (since 2012)
- Work Group 3 Pre-market: Software as a Medical Device Chair (2023)
- Work Group 9 UDI & Nomenclature Member (since 2019)



## Outline



Medical Devices





4

#### Collaboration with Japan





# **Collaboration with Japan**

#### **Pharmaceutical Working Group**

- 1. Developed Position Paper and Q&As for New Drug Review Scheme; 6 cases were adopted and 5 were completed..
- 2. Established the Information Sharing model of post-marketing surveillance information.


#### Medical Devices Working Group

- Exchanged experiences and regulatory innovation on digital transformation:
- DASH for SaMDs; AI/ML-based SaMDs
- Electronic submission system
- E-labeling system
- Cybersecurity

36.8

VACCINE

## Progress for the QMS Working Group of Medical Devices



## Outline

- 1 Medicinal Products
  - Medical Devices











## **Future Prospects**

#### To Complete Accessible Information Platform

To Establish Forward-looking Legislation To Establish Professional Review Team

> To Optimize Quality Compliance & Management

#### To Enhance International Regulatory Collaboration

To Provide Efficient Communication & Services





# Thank You!



